169 related articles for article (PubMed ID: 31090656)
1. Incidence and Clinical Impact of Anti-TNFα Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolit Survey.
Lesage C; Longvert C; Prey S; Maanaoui S; Dréno B; Machet L; Zehou O; Kramkimel N; Jeudy G; Skowron F; Aubin F; Visseaux L; Mansard S; Dereure O; Lesage FX; Guillot B;
J Immunother; 2019 Jun; 42(5):175-179. PubMed ID: 31090656
[TBL] [Abstract][Full Text] [Related]
2. The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis.
Tandon P; Bourassa-Blanchette S; Bishay K; Parlow S; Laurie SA; McCurdy JD
J Immunother; 2018 Apr; 41(3):101-108. PubMed ID: 29401166
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma Patients.
Garcia-Neuer M; Marmarelis ME; Jangi SR; Luke JJ; Ibrahim N; Davis M; Weinberg J; Donahue H; Bailey N; Hodi FS; Buchbinder EL; Ott PA
Cancer Immunol Res; 2017 Apr; 5(4):286-291. PubMed ID: 28373217
[TBL] [Abstract][Full Text] [Related]
4. Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control.
Hughes MS; Zheng H; Zubiri L; Molina GE; Chen ST; Mooradian MJ; Allen IM; Reynolds KL; Dougan M
Cancer Med; 2019 Sep; 8(11):4986-4999. PubMed ID: 31286682
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma.
Abu-Sbeih H; Ali FS; Qiao W; Lu Y; Patel S; Diab A; Wang Y
Cancer Immunol Immunother; 2019 Apr; 68(4):553-561. PubMed ID: 30666357
[TBL] [Abstract][Full Text] [Related]
6. Association of Antibiotic Exposure With Survival and Toxicity in Patients With Melanoma Receiving Immunotherapy.
Mohiuddin JJ; Chu B; Facciabene A; Poirier K; Wang X; Doucette A; Zheng C; Xu W; Anstadt EJ; Amaravadi RK; Karakousis GC; Mitchell TC; Huang AC; Shabason JE; Lin A; Swisher-McClure S; Maity A; Schuchter LM; Lukens JN
J Natl Cancer Inst; 2021 Feb; 113(2):162-170. PubMed ID: 32294209
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study.
Abu-Sbeih H; Ali FS; Alsaadi D; Jennings J; Luo W; Gong Z; Richards DM; Charabaty A; Wang Y
J Immunother Cancer; 2018 Dec; 6(1):142. PubMed ID: 30518410
[TBL] [Abstract][Full Text] [Related]
8. Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis.
Mooradian MJ; Wang DY; Coromilas A; Lumish M; Chen T; Giobbie-Hurder A; Johnson DB; Sullivan RJ; Dougan M
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414860
[TBL] [Abstract][Full Text] [Related]
9. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease : A Cohort Study.
van der Kooij MK; Suijkerbuijk KPM; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; van Breeschoten J; van den Eertwegh AJM; de Groot JWB; Haanen JBAG; Hospers GAP; Piersma D; van Rijn RS; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van Zeijl MCT; Wouters MWJM; Dekkers OM; Kapiteijn E
Ann Intern Med; 2021 May; 174(5):641-648. PubMed ID: 33587686
[TBL] [Abstract][Full Text] [Related]
11. Impact of Selective Immunosuppressive Therapy on Subsequent Immune-Related Adverse Events After Immune Checkpoint Inhibitor-Induced Colitis Treatment.
Pizuorno Machado A; Shatila M; Glitza Oliva IC; Altan M; Siddiqui B; Zhou Y; Varatharajalu K; Zhang HC; Thomas A; Wang Y
Am J Clin Oncol; 2023 Aug; 46(8):360-365. PubMed ID: 37219360
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?
Cheung VTF; Gupta T; Olsson-Brown A; Subramanian S; Sasson SC; Heseltine J; Fryer E; Collantes E; Sacco JJ; Pirmohamed M; Simmons A; Klenerman P; Tuthill M; Protheroe AS; Chitnis M; Fairfax BP; Payne MJ; Middleton MR; Brain O
Br J Cancer; 2020 Jul; 123(2):207-215. PubMed ID: 32418993
[TBL] [Abstract][Full Text] [Related]
13. High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer.
Tone M; Izumo T; Awano N; Kuse N; Inomata M; Jo T; Yoshimura H; Minami J; Takada K; Miyamoto S; Kunitoh H
Thorac Cancer; 2019 Oct; 10(10):2006-2012. PubMed ID: 31482678
[TBL] [Abstract][Full Text] [Related]
14. The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy.
Puza CJ; Bressler ES; Terando AM; Howard JH; Brown MC; Hanks B; Salama AKS; Beasley GM
J Surg Res; 2019 Apr; 236():209-215. PubMed ID: 30694757
[TBL] [Abstract][Full Text] [Related]
15. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.
Sussman TA; Li H; Hobbs B; Funchain P; McCrae KR; Khorana AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436486
[TBL] [Abstract][Full Text] [Related]
16. Value of PD-L1, PD-1, and CTLA-4 Expression in the Clinical Practice as Predictors of Response to Nivolumab and Ipilimumab in Monotherapy in Patients With Advanced Stage Melanoma.
Santos-Briz A; Cañueto J; Carmen SD; Barrios B; Yuste M; Bellido L; Ludeña MD; Román C
Am J Dermatopathol; 2021 Jun; 43(6):423-428. PubMed ID: 33395045
[TBL] [Abstract][Full Text] [Related]
17. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab.
Friedlander P; Wood K; Wassmann K; Christenfeld AM; Bhardwaj N; Oh WK
J Immunother Cancer; 2018 Sep; 6(1):90. PubMed ID: 30227886
[TBL] [Abstract][Full Text] [Related]
18. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis.
Baki E; Zwickel P; Zawierucha A; Ehehalt R; Gotthardt D; Stremmel W; Gauss A
World J Gastroenterol; 2015 Mar; 21(11):3282-90. PubMed ID: 25805935
[TBL] [Abstract][Full Text] [Related]
19. Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma.
Favara DM; Spain L; Au L; Clark J; Daniels E; Diem S; Chauhan D; Turajlic S; Powell N; Larkin JM; Yousaf N
ESMO Open; 2020 Jul; 5(4):. PubMed ID: 32641348
[TBL] [Abstract][Full Text] [Related]
20. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
